Drug profile · INN
nogapendekin alfa inbakicept
ANKTIVA
nogapendekin alfa inbakicept (ANKTIVA) is a interleukin-15 receptor agonist.
Drug details — nogapendekin alfa inbakicept
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
nogapendekin alfa inbakicept (ANKTIVA) is a interleukin-15 receptor agonist.
Key facts
Mechanism of action
Interleukin-15 receptor agonist
Primary target: Interleukin-15 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles
ImmunityBio is navigating a complex regulatory landscape for its bladder cancer therapy, Anktiva. This article provides insights into upcoming FDA decisions and their impact on the pharmaceutical industry.
ImmunityBio's Anktiva Expansion: FDA Decision Date Insights
ImmunityBio has secured a decision date from the FDA regarding Anktiva's expansion. This article explores the implications for pharma stakeholders.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
ImmunityBio hit with class action lawsuit after FDA determined company made false claims about Anktiva bladder cancer drug's capabilities beyond approved use.
SFDA Accelerated Approval Oncology: Impact on Innovative Drugs in Saudi Arabia
The SFDA's Accelerated Approval program significantly impacts the availability of innovative oncology drugs, such as Keytruda, for cancer patients in Saudi Arabia.
Related & competitor drugs
Frequently asked questions
What is nogapendekin alfa inbakicept?
nogapendekin alfa inbakicept (ANKTIVA) is a interleukin-15 receptor agonist.
What is the brand name for nogapendekin alfa inbakicept?
ANKTIVA is a marketed brand name for nogapendekin alfa inbakicept. Check FDA Drugs@FDA for the current US label holder and prescribing information.